Evidence map›Paper›PMID 41333181›Full record

ArticleAdvances in radiation oncology2025

Novel Molecular Subtyping Predicts Locoregional Recurrence in Triple-negative Breast Cancer.

Shali Shao, Wei Shi, Li Zhang, Qixian Zhang, Jin Meng, Zhaozhi Yang, Miao Mo, Zhen Zhang, Xiaomao Guo, Xiaoli Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shali ShaoDepartment of Radiation Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Wei ShiDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Li ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qixian ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jin MengDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhaozhi YangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Miao MoDepartment of Cancer Prevention and Clinical Statistics Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhen ZhangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaomao GuoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaoli YuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Immunohistochemistry (IHC)-based molecular subtyping provides a comprehensive profile of triple-negative breast cancer (TNBC). We aimed to elucidate patterns of locoregional recurrence (LRR) in different subtypes of TNBC. Methods and Materials: In this study, 352 patients with breast cancer treated with mastectomy and postmastectomy radiation therapy from November 2019 to March 2022 were retrospectively analyzed. Based on IHC, these patients were classified into the basal-like immune-suppressed (BLIS) and non-BLIS groups. We compared LRR as the first event, disease-free survival, and overall survival (OS) between the 2 groups. Univariate and multivariate analysis was performed. Results: The median follow-up time was 44.6 months. Twenty-six LRR (including 9 isolated LRR) and 70 distant metastases (DMs) were observed. The cumulative incidence of LRR was significantly different between the 2 groups, with an LRR rate of 5.8% in the non-BLIS group and 14.9% in the BLIS group ( Conclusions: This study demonstrated that the BLIS subtype appears to be at a higher risk of developing LRR, and IHC-based molecular subtyping might be used as prognostic biomarkers to guide postmastectomy radiation therapy in patients with TNBC. New strategies that improve locoregional control rates in patients with BLIS are warranted.

Identifiers

PMID41333181
PMCPMC12666700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.